PL3446565T3 - Sposoby leczenia przyrostu masy ciała wywołanego lekami przeciwpsychotycznymi - Google Patents
Sposoby leczenia przyrostu masy ciała wywołanego lekami przeciwpsychotycznymiInfo
- Publication number
- PL3446565T3 PL3446565T3 PL18198977.3T PL18198977T PL3446565T3 PL 3446565 T3 PL3446565 T3 PL 3446565T3 PL 18198977 T PL18198977 T PL 18198977T PL 3446565 T3 PL3446565 T3 PL 3446565T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- weight gain
- induced weight
- antipsychotic
- treating
- Prior art date
Links
- 230000000561 anti-psychotic effect Effects 0.000 title 1
- 230000004584 weight gain Effects 0.000 title 1
- 235000019786 weight gain Nutrition 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Child & Adolescent Psychology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37612010P | 2010-08-23 | 2010-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3446565T3 true PL3446565T3 (pl) | 2024-04-02 |
Family
ID=45723770
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18198977.3T PL3446565T3 (pl) | 2010-08-23 | 2011-08-23 | Sposoby leczenia przyrostu masy ciała wywołanego lekami przeciwpsychotycznymi |
| PL11820517T PL2608670T3 (pl) | 2010-08-23 | 2011-08-23 | Sposoby leczenia przyrostu masy ciała wywołanego neuroleptykiem |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11820517T PL2608670T3 (pl) | 2010-08-23 | 2011-08-23 | Sposoby leczenia przyrostu masy ciała wywołanego neuroleptykiem |
Country Status (20)
| Country | Link |
|---|---|
| US (11) | US8778960B2 (pl) |
| EP (3) | EP3446565B1 (pl) |
| JP (1) | JP5684388B2 (pl) |
| AU (4) | AU2011293502B2 (pl) |
| CA (1) | CA2807965C (pl) |
| CY (1) | CY1121128T1 (pl) |
| DK (2) | DK2608670T3 (pl) |
| ES (2) | ES2969625T3 (pl) |
| FI (1) | FI3446565T3 (pl) |
| HR (2) | HRP20240109T1 (pl) |
| HU (2) | HUE065427T2 (pl) |
| LT (2) | LT2608670T (pl) |
| NZ (1) | NZ606730A (pl) |
| PL (2) | PL3446565T3 (pl) |
| PT (2) | PT3446565T (pl) |
| RS (2) | RS58312B1 (pl) |
| SI (2) | SI2608670T1 (pl) |
| SM (2) | SMT201900051T1 (pl) |
| TR (1) | TR201900097T4 (pl) |
| WO (1) | WO2012027359A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2445502B2 (en) * | 2009-06-25 | 2022-09-28 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
| HRP20191029T1 (hr) | 2009-12-04 | 2019-09-20 | Alkermes Pharma Ireland Limited | Derivati morfinana radi liječenja predoziranja lijekom |
| HRP20240109T1 (hr) | 2010-08-23 | 2024-03-29 | Alkermes Pharma Ireland Limited | Postupci za liječenje povećanja tjelesne težine induciranog antipsihoticima |
| US9211293B2 (en) | 2011-12-15 | 2015-12-15 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
| EP3003311A2 (en) | 2013-05-24 | 2016-04-13 | Alkermes Pharma Ireland Limited | Methods for treating depressive symptoms |
| JP2016519161A (ja) | 2013-05-24 | 2016-06-30 | アルカームス ファーマ アイルランド リミテッド | モルファン及びモルフィナン類似物及び使用の方法 |
| WO2020006367A1 (en) * | 2018-06-29 | 2020-01-02 | Tufts Medical Center, Inc. | Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions |
| EP4243768A1 (en) | 2020-11-12 | 2023-09-20 | Alkermes Pharma Ireland Limited | Immediate release multilayer tablet |
| WO2023105103A1 (es) | 2022-06-17 | 2023-06-15 | Mesoestetic Pharma Group, S.L | Composición cosmética sinérgica despigmentante de la piel |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES252980A1 (es) | 1958-10-30 | 1960-11-01 | Boehringer Sohn Ingelheim | Procedimiento para la obtencion de nuevas sales cuaternarias, terapéuticamente valiosas, de la normorfina y de sus derivados |
| BE634402A (fr) | 1962-07-02 | 1964-01-02 | British Drug Houses Ltd | Dérivés de l'hydrophénanthrène et leurs procédés de préparation |
| GB981046A (en) | 1962-07-02 | 1965-01-20 | British Drug Houses Ltd | Hexahydro-4ah-8,9c-iminoethano phenanthro-[4,5-b,c,d]-furan derivatives |
| US3332950A (en) | 1963-03-23 | 1967-07-25 | Endo Lab | 14-hydroxydihydronormorphinone derivatives |
| US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| CH581624A5 (pl) | 1970-08-14 | 1976-11-15 | Sumitomo Chemical Co | |
| US3856795A (en) | 1972-04-25 | 1974-12-24 | American Home Prod | Process for preparation of secondary amines from tertiary amines |
| DE2254298A1 (de) | 1972-11-06 | 1974-05-16 | Boehringer Sohn Ingelheim | Neue (heteroarylmethyl)-normorphine, deren saeureadditionssalze, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
| US4032529A (en) | 1974-09-20 | 1977-06-28 | Sterling Drug Inc. | Aminomethanobenzazocine intermediates |
| US3957793A (en) | 1974-09-20 | 1976-05-18 | Sterling Drug Inc. | Hydroxyiminobenzazocines |
| US4127577A (en) | 1975-11-24 | 1978-11-28 | Sterling Drug Inc. | Aminomethanobenzazocine process |
| US4205171A (en) | 1976-01-12 | 1980-05-27 | Sterling Drug Inc. | Aminomethanobenzazocines and nitromethanobenzazocines |
| US4161597A (en) | 1976-12-20 | 1979-07-17 | Research Corporation | N-alkyl-14-hydroxymorphinans and derivatives |
| US4100228A (en) | 1977-04-04 | 1978-07-11 | The Dow Chemical Company | Transparent impact styrene polymer structure |
| US4176186A (en) | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
| US4373139A (en) | 1979-04-30 | 1983-02-08 | Motorola, Inc. | Detectors |
| US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
| FR2514644A1 (fr) | 1981-10-19 | 1983-04-22 | Sanofi Sa | Composition pharmaceutique a action antagoniste peripherique des opiaces |
| DE3220831A1 (de) | 1982-06-03 | 1983-12-08 | Boehringer Ingelheim KG, 6507 Ingelheim | N-(2-methoxyethyl)-noroxymorphon, dessen saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu deren herstellung |
| US4451470A (en) | 1982-07-06 | 1984-05-29 | E. I. Du Pont De Nemours And Company | Analgesic, antagonist, and/or anorectic 14-fluoromorphinans |
| US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US4649200A (en) | 1986-05-08 | 1987-03-10 | Regents Of The University Of Minnesota | Substituted pyrroles with opioid receptor activity |
| US4939264A (en) | 1986-07-14 | 1990-07-03 | Abbott Laboratories | Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies |
| US4929622A (en) | 1987-09-24 | 1990-05-29 | Hoechst-Roussel Pharmaceuticals, Inc. | 2,6-Methanopyrrolo-3-benzazocines |
| US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| US5258386A (en) | 1991-06-05 | 1993-11-02 | The United States Of America As Represented By The Secretary Of The Army | (+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents |
| US5607941A (en) | 1992-06-26 | 1997-03-04 | Boehringer Ingelheim Kg | Useful for treating neurodegenerative diseases |
| SE9103745D0 (sv) | 1991-12-18 | 1991-12-18 | Wikstroem Haakan | Aryl-triflates and related compounds |
| JPH05231100A (ja) | 1992-02-25 | 1993-09-07 | Hazama Gumi Ltd | トンネル用通気仕切り |
| US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| EP0632041A1 (en) | 1993-07-01 | 1995-01-04 | Katholieke Universiteit Nijmegen | New morphine derivatives having improved analgesic and narcotic properties |
| US5650173A (en) | 1993-11-19 | 1997-07-22 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
| EP0729353B2 (en) | 1993-11-19 | 2012-09-12 | Alkermes, Inc. | Preparation of biodegradable microparticles containing a biologically active agent |
| EG23659A (en) | 1995-03-24 | 2007-03-26 | Lilly Co Eli | Process and crystal forms of methyl-thieno-benzodiazepine |
| AR005423A1 (es) | 1996-01-10 | 1999-06-23 | Smithkline Beecham Spa | Derivados morfinoides condensados con heterociclos (ii), su uso como sustancia terapeutica y para preparar medicamentos, composiciones farmaceuticasque los contienen y procedimiento para preparar dichos derivados. |
| GB9616253D0 (en) | 1996-08-01 | 1996-09-11 | Johnson Matthey Plc | Preparation of narcotic analgesics |
| ES2121553B1 (es) | 1996-12-23 | 1999-06-16 | Univ Santiago Compostela | Nuevos endoperoxidos morfinicos funcionalizados en posiciones c-6 y c-14 del anillo c y procedimiento para su obtencion. |
| GB9709972D0 (en) | 1997-05-19 | 1997-07-09 | Pfizer Ltd | Tetrazoles |
| GB9912411D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
| EP1210084A4 (en) | 1999-08-13 | 2002-11-13 | Southern Res Inst | PYRIDOMORPHINANS, THIENOMORPHINANS AND THEIR USE |
| US6495166B1 (en) | 1999-11-12 | 2002-12-17 | Alkermes Controlled Therapeutics Inc. | Apparatus and method for preparing microparticles using in-line solvent extraction |
| AU784541B2 (en) | 1999-11-29 | 2006-04-27 | Adolor Corporation | Novel methods and compositions involving opioids and antagonists thereof |
| DE60109960T2 (de) | 2000-10-31 | 2006-02-16 | Rensselaer Polytechnic Institute | 8-substituierte 2,6-methano-3-benzazocine und 3-substituierte morphinane als opioidrezeptorbindende agenzien |
| US7375082B2 (en) | 2002-02-22 | 2008-05-20 | Shire Llc | Abuse-resistant hydrocodone compounds |
| WO2003079945A1 (en) | 2002-03-20 | 2003-10-02 | Euro-Celtique S.A. | Method of administering buprenorphine to treat depression |
| ES2249722T3 (es) | 2002-05-30 | 2006-04-01 | Eli Lilly And Company | Antagonistas de receptor de opioides. |
| DE10229842A1 (de) | 2002-07-03 | 2004-02-05 | Helmut Prof. Dr. Schmidhammer | Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung |
| WO2004007449A1 (en) | 2002-07-16 | 2004-01-22 | Rensselaer Polytechnic Institute | Process for conversion of phenols to carboxamides via the succinimide esters |
| WO2004045562A2 (en) | 2002-11-18 | 2004-06-03 | The Mclean Hospital Corporation | Mixed kappa/mu opioids and uses thereof |
| US20040192715A1 (en) | 2003-02-05 | 2004-09-30 | Mark Chasin | Methods of administering opioid antagonists and compositions thereof |
| MXPA05011557A (es) | 2003-04-29 | 2006-03-09 | Orexigen Therapeutics Inc | Composiciones para afectar perdida de peso. |
| CA2553309A1 (en) * | 2004-04-22 | 2005-11-03 | Mor Research Applications Ltd. | Method of food intake management |
| KR101204751B1 (ko) | 2004-05-14 | 2012-11-27 | 얀센 파마슈티카 엔.브이. | 카복사미도 아편유사약물 화합물 |
| US20060063792A1 (en) | 2004-09-17 | 2006-03-23 | Adolor Corporation | Substituted morphinans and methods of their use |
| MX2007005389A (es) * | 2004-11-05 | 2007-12-07 | Rensselaer Polytech Inst | 4-hidroxibenzomorfanos. |
| CN101171010B (zh) | 2005-03-07 | 2014-09-17 | 芝加哥大学 | 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途 |
| ES2480390T3 (es) | 2005-07-21 | 2014-07-28 | Rensselaer Polytechnic Institute | 2,6-metano-3-benzazocinas 8-carboxamido sustituidas y morfanos 3-carboxamido sustituidos como ligandos de los receptores opioides |
| US20070099947A1 (en) | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
| WO2007067714A2 (en) * | 2005-12-08 | 2007-06-14 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| WO2007089934A2 (en) | 2006-02-01 | 2007-08-09 | Alkermes, Inc. | Methods of treating alcoholism and alcohol related disorders using combination drug therapy and swellable polymers |
| RU2009112685A (ru) | 2006-09-20 | 2010-10-27 | Маллинкродт Инк. (Us) | Получение замещенных морфинан-6-онов и их солей и промежуточных соединений |
| DK2073636T3 (da) | 2006-10-17 | 2012-11-19 | Penick Corp | Fremgangsmåde til fremstilling af oxymorphon |
| MX2009005461A (es) | 2006-11-22 | 2009-08-28 | Progenics Pharm Inc | N-oxidos de analogos de 4,5-epoxi-morfinano. |
| US9040726B2 (en) | 2007-03-06 | 2015-05-26 | Mallinckrodt Llc | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts |
| EP2134330B1 (en) | 2007-03-19 | 2013-05-08 | Acadia Pharmaceuticals Inc. | Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics |
| MX2009012281A (es) | 2007-05-16 | 2009-12-01 | Rensselaer Polytech Inst | Opioides heterociclicos de anillo fusionado. |
| WO2009009083A1 (en) | 2007-07-12 | 2009-01-15 | The Mclean Hospital Corporation | R(-)-2-methoxy-11-hydroxyaporphine and derivatives thereof |
| JP5581211B2 (ja) | 2007-08-09 | 2014-08-27 | レンセラール ポリテクニック インスティチュート | 第四級オピオイドカルボキサミド |
| AU2009214500B2 (en) | 2008-02-14 | 2014-10-23 | Alkermes, Inc. | Selective opioid compounds |
| WO2009126931A2 (en) | 2008-04-11 | 2009-10-15 | Xvasive, Inc. | Combination therapy for bipolar disorder |
| AU2009274147B2 (en) | 2008-07-21 | 2014-09-04 | Rensselaer Polytechnic Institute | Large substituent, non-phenolic amine opioids |
| AU2009342654B2 (en) | 2009-03-19 | 2013-09-05 | Alkermes Pharma Ireland Limited | Morphinan derivatives with high oral bioavailability |
| US20120149724A1 (en) | 2009-06-04 | 2012-06-14 | The General Hospital Corporation | Modulating endogenous beta-endorphin levels |
| EP2445502B2 (en) | 2009-06-25 | 2022-09-28 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
| HRP20191029T1 (hr) | 2009-12-04 | 2019-09-20 | Alkermes Pharma Ireland Limited | Derivati morfinana radi liječenja predoziranja lijekom |
| ES2582306T3 (es) | 2010-03-22 | 2016-09-12 | Rensselaer Polytechnic Institute | Derivados de morfinano que contienen un grupo carboxamida como ligandos de receptores opioides |
| ES2708726T3 (es) | 2010-07-08 | 2019-04-10 | Alkermes Pharma Ireland Ltd | Proceso para la síntesis de morfinanos sustituidos |
| PL2601196T3 (pl) | 2010-08-04 | 2014-09-30 | Mallinckrodt Llc | N-demetylowanie 6-ketomorfinanów |
| HRP20240109T1 (hr) | 2010-08-23 | 2024-03-29 | Alkermes Pharma Ireland Limited | Postupci za liječenje povećanja tjelesne težine induciranog antipsihoticima |
| ES2604931T3 (es) | 2010-12-23 | 2017-03-10 | Phoenix Pharmalabs, Inc. | Nuevos morfinanos útiles como analgésicos |
| US9211293B2 (en) | 2011-12-15 | 2015-12-15 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
| RS58322B1 (sr) | 2011-12-15 | 2019-03-29 | Alkermes Pharma Ireland Ltd | Samidorfan (alks 33) u kombinaciji sa buprenorfinom za lečenje depresivnih poremećaja |
| EP3003311A2 (en) | 2013-05-24 | 2016-04-13 | Alkermes Pharma Ireland Limited | Methods for treating depressive symptoms |
| JP2016519161A (ja) | 2013-05-24 | 2016-06-30 | アルカームス ファーマ アイルランド リミテッド | モルファン及びモルフィナン類似物及び使用の方法 |
-
2011
- 2011-08-23 HR HRP20240109TT patent/HRP20240109T1/hr unknown
- 2011-08-23 PL PL18198977.3T patent/PL3446565T3/pl unknown
- 2011-08-23 WO PCT/US2011/048794 patent/WO2012027359A1/en not_active Ceased
- 2011-08-23 LT LTEP11820517.8T patent/LT2608670T/lt unknown
- 2011-08-23 FI FIEP18198977.3T patent/FI3446565T3/fi active
- 2011-08-23 LT LTEP18198977.3T patent/LT3446565T/lt unknown
- 2011-08-23 RS RS20190080A patent/RS58312B1/sr unknown
- 2011-08-23 EP EP18198977.3A patent/EP3446565B1/en active Active
- 2011-08-23 DK DK11820517.8T patent/DK2608670T3/en active
- 2011-08-23 EP EP11820517.8A patent/EP2608670B1/en active Active
- 2011-08-23 HU HUE18198977A patent/HUE065427T2/hu unknown
- 2011-08-23 DK DK18198977.3T patent/DK3446565T3/da active
- 2011-08-23 TR TR2019/00097T patent/TR201900097T4/tr unknown
- 2011-08-23 CA CA2807965A patent/CA2807965C/en active Active
- 2011-08-23 JP JP2013526092A patent/JP5684388B2/ja active Active
- 2011-08-23 EP EP23204861.1A patent/EP4306164A3/en active Pending
- 2011-08-23 HU HUE11820517A patent/HUE041981T2/hu unknown
- 2011-08-23 US US13/215,718 patent/US8778960B2/en active Active
- 2011-08-23 PT PT181989773T patent/PT3446565T/pt unknown
- 2011-08-23 SI SI201131664T patent/SI2608670T1/sl unknown
- 2011-08-23 ES ES18198977T patent/ES2969625T3/es active Active
- 2011-08-23 RS RS20240080A patent/RS65091B1/sr unknown
- 2011-08-23 PT PT11820517T patent/PT2608670T/pt unknown
- 2011-08-23 ES ES11820517T patent/ES2705726T3/es active Active
- 2011-08-23 AU AU2011293502A patent/AU2011293502B2/en active Active
- 2011-08-23 SM SM20190051T patent/SMT201900051T1/it unknown
- 2011-08-23 SM SM20240030T patent/SMT202400030T1/it unknown
- 2011-08-23 NZ NZ606730A patent/NZ606730A/en unknown
- 2011-08-23 SI SI201132099T patent/SI3446565T1/sl unknown
- 2011-08-23 HR HRP20190169TT patent/HRP20190169T1/hr unknown
- 2011-08-23 PL PL11820517T patent/PL2608670T3/pl unknown
-
2014
- 2014-06-05 US US14/297,171 patent/US9126977B2/en active Active
-
2015
- 2015-04-15 AU AU2015201907A patent/AU2015201907B2/en active Active
- 2015-07-30 US US14/813,260 patent/US9517235B2/en active Active
-
2016
- 2016-11-03 US US15/342,263 patent/US9943514B2/en active Active
-
2017
- 2017-01-20 AU AU2017200396A patent/AU2017200396B2/en active Active
-
2018
- 2018-03-16 US US15/923,084 patent/US10300054B2/en active Active
- 2018-04-05 AU AU2018202410A patent/AU2018202410B2/en active Active
-
2019
- 2019-01-16 CY CY191100054T patent/CY1121128T1/el unknown
- 2019-04-22 US US16/390,531 patent/US10716785B2/en active Active
-
2020
- 2020-06-12 US US16/899,708 patent/US11185541B2/en active Active
- 2020-10-15 US US17/071,166 patent/US11351166B2/en active Active
- 2020-10-15 US US17/071,236 patent/US11241425B2/en active Active
-
2021
- 2021-10-20 US US17/505,896 patent/US11793805B2/en active Active
-
2023
- 2023-09-21 US US18/371,071 patent/US12194035B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180882T1 (hr) | Sredstva za i postupci liječenja dlbcl | |
| IL220939A0 (en) | Compounds and methods | |
| EP2523664A4 (en) | COMPOUNDS AND METHODS | |
| PL2652193T3 (pl) | Obróbka | |
| GB201010196D0 (en) | Methods | |
| IL220812A0 (en) | Compounds and methods | |
| LT2608670T (lt) | Antipsichotikų sukelto padidėjusio svorio sumažinimo būdai | |
| ZA201204641B (en) | Method for preparing and detoxifying | |
| IL225298A0 (en) | Lamina grafting system | |
| EP2621497A4 (en) | ASSOCIATION TREATMENT FOR ROSE ACNE | |
| IL220594A0 (en) | Treatment method | |
| EP2523560A4 (en) | CONNECTIONS AND METHODS | |
| EP2571161A4 (en) | AMPLIFIER | |
| IL222479A (en) | Tissue Engineering Methods | |
| GB201013573D0 (en) | Treatment | |
| EP2560679A4 (en) | TREATMENT OF ECZEMA | |
| GB201011367D0 (en) | Methods | |
| IL223436A (en) | Methods for preparing tetranor - pgdm and tetranor - pgjm | |
| GB201020805D0 (en) | Radiotherapeutic apparatus | |
| GB201020796D0 (en) | Radiotherapeutic apparatus | |
| GB201009479D0 (en) | Anti-malarial implants | |
| TWM398488U (en) | Improved structure for casters | |
| TWM400948U (en) | Improved structure for casters |